The last few years, new therapies targeting the epidermal growth factor receptor (EGFR)
have shown their efficacy in the treatment of several types of cancer. Monoclonal antibodies …

Background: Skin toxicities are frequent in patients receiving epidermal growth factor
receptor (EGFR) antagonists. Grading and management of these skin reactions are poorly …

Purpose Erlotinib is an epidermal growth factor receptor inhibitor approved for patients with
advanced non–small-cell lung cancer (NSCLC) whose epidermal growth factor receptor …

Objective: To compile evidence from randomized controlled trials, case series, and case
reports to identify the effectiveness of various therapeutic agents for the treatment and …

OBJECTIVES: To review the general toxicity profile of EGFR-targeted therapies and the
management of the most common side effect, skin toxicity. DATA SOURCES: Research …

The use of epidermal growth factor receptor (EGFR) inhibitors in several epithelial tumors
has increased considerably in recent years. Currently, they are approved in non-small cell …

Biologic agents targeting the epidermal growth factor receptor (EGFR) have emerged as a
robust treatment option for various solid tumors. Despite lower systemic side effects than …

Background Epidermal growth factor receptor inhibitors (EGFRI) produce various
dermatologic side effects in the majority of patients, and guidelines are crucial for the …

A comment on this article appears in" Radiation-induced prevention of erlotinib-induced skin
rash is transient: a new aspect toward the understanding of epidermal growth factor receptor …

Epidermal growth factor receptor inhibitors (EGFRIs) are increasingly being used for
malignancies of epithelial origin. Though these therapies are better tolerated than …